4.7 Article

MicroRNA-155 Regulates Inflammatory Cytokine Production in Tumor-associated Macrophages via Targeting C/EBPβ

期刊

CELLULAR & MOLECULAR IMMUNOLOGY
卷 6, 期 5, 页码 343-352

出版社

CHIN SOCIETY IMMUNOLOGY
DOI: 10.1038/cmi.2009.45

关键词

C/EBP beta; inflammatory cytokine; miR-155; TAM; transcription factor

资金

  1. NSFC, China [30425025, 30730086]
  2. The Ministry of Health of China [2008ZX10002-019]

向作者/读者索取更多资源

Macrophages (M phi) are prominent components of solid tumors and exhibit distinct phenotypes in different microenvironments. We have recently found that tumors can alter the normal developmental process of M phi to trigger transient activation of monocytes, but the underlying regulatory mechanisms are incompletely understood. Here, we showed that the protein expression of transcription factor C/EBP beta was markedly elevated in tumor-associated M phi both in vitro and human tumors in situ. The expression of C/EBP beta protein correlated with cytokine production in tumor-activated monocytes. Moreover, we found that C/EBP beta expression was regulated at the post-transcriptional level and correlated with sustained reduction of microRNA-155 (miR-155) in tumor-activated monocytes. Bioinformatic analysis revealed that C/EBP beta is a potential target of miR-155 and luciferase assay confirmed that C/EBP beta translation is suppressed by miR-155 through interaction with the 3'UTR of C/EBP beta mRNA. Further analysis showed that induction of miR-155 suppressed C/EBP beta protein expression as well as cytokine production in tumor-activated monocytes, an effect which could be mimicked by silencing of C/EBP beta. These results indicate that tumor environment causes a sustained reduction of miR-155 in monocytes/M phi which in turn regulates the functional activities of monocytes/M phi by releasing the translational inhibition of transcription factor C/EBP beta. Cellular & Molecular Immunology. 2009;6(5):343-352.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据